Anna E Vilgelm, M.D., Ph.D

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

1. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Vilgelm AE, Richmond A (2019) Front Immunol : 333
   › Primary publication · 30873179 (PubMed) · PMC6400988 (PubMed Central)
2. Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A (2018) Cancer Immunol Res 6(10): 1186-1198
   › Primary publication · 30108045 (PubMed) · PMC6170679 (PubMed Central)
3. MDM2 Antagonists Counteract Drug-Induced DNA Damage. Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A (2017) EBioMedicine : 43-55
   › Primary publication · 29030058 (PubMed) · PMC5652019 (PubMed Central)
4. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses. Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A (2017) Clin Cancer Res 23(13): 3371-3384
   › Primary publication · 28003307 (PubMed) · PMC5479746 (PubMed Central)
5. Combinatorial approach to cancer immunotherapy: strength in numbers. Vilgelm AE, Johnson DB, Richmond A (2016) J Leukoc Biol 100(2): 275-90
   › Primary publication · 27256570 (PubMed)
6. Using avatars to win the fight over BRAF inhibitor resistance. Vilgelm AE, Richmond A (2016) Pigment Cell Melanoma Res 29(4): 398-9
   › Primary publication · 27185579 (PubMed)
7. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Nat Commun : 10582
   › Primary publication · 26822383 (PubMed) · PMC4740184 (PubMed Central)
8. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A (2016) J Natl Cancer Inst 108(6): djv406
   › Primary publication · 26719346 (PubMed) · PMC4849355 (PubMed Central)
9. Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses. Vilgelm A, Richmond A (2015) Oncoimmunology 4(8): e1009299
   › Primary publication · 26405565 (PubMed) · PMC4570092 (PubMed Central)
10. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2015) Clin Cancer Res 21(23): 5338-48
    › Primary publication · 26152738 (PubMed) · PMC4668227 (PubMed Central)
11. Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A (2015) Cancer Res 75(1): 181-93
    › Primary publication · 25398437 (PubMed) · PMC4286469 (PubMed Central)
12. Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment. Hockemeyer K, Janetopoulos C, Terekhov A, Hofmeister W, Vilgelm A, Costa L, Wikswo JP, Richmond A (2014) Biomicrofluidics 8(4): 044105
    › Primary publication · 25379090 (PubMed) · PMC4189212 (PubMed Central)
13. Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. Davis TA, Vilgelm AE, Richmond A, Johnston JN (2013) J Org Chem 78(21): 10605-16
    › Primary publication · 24127627 (PubMed) · PMC3880828 (PubMed Central)
14. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2013) EMBO Mol Med 5(1): 149-66
    › Primary publication · 23180582 (PubMed) · PMC3569660 (PubMed Central)
15. RAF265 inhibits the growth of advanced human melanoma tumors. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2012) Clin Cancer Res 18(8): 2184-98
    › Primary publication · 22351689 (PubMed) · PMC3724517 (PubMed Central)
16. [The coordinated interaction of multifunctional members of p53 family determines many key processes in multicellular organisms]. Vilgelm AE, Zaika AI, Prasolov VS (2011) Mol Biol (Mosk) 45(1): 180-97
    › Primary publication · 21485507 (PubMed)
17. Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors. Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, Zaika A (2010) Oncogene 29(43): 5861-8
    › Primary publication · 20676143 (PubMed) · PMC4152004 (PubMed Central)
18. Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM, Zaika A (2010) Gastroenterology 139(4): 1333-43
    › Primary publication · 20547161 (PubMed) · PMC2949494 (PubMed Central)
19. Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI (2010) Mol Cancer Ther 9(3): 693-705
    › Primary publication · 20197393 (PubMed) · PMC2838189 (PubMed Central)
20. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Vilgelm A, El-Rifai W, Zaika A (2008) Drug Resist Updat 11(4-5): 152-63
    › Primary publication · 18801697 (PubMed) · PMC2585826 (PubMed Central)
21. Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Wei J, O'Brien D, Vilgelm A, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM, Zaika A (2008) Gastroenterology 134(5): 1412-23
    › Primary publication · 18343378 (PubMed) · PMC2430883 (PubMed Central)
22. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, El-Rifai W, Zaika A (2008) Oncogene 27(15): 2170-6
    › Primary publication · 17952118 (PubMed) · PMC4066670 (PubMed Central)
23. [RNA interference: biology and perspectives of application in biomedicine and biotechnology]. Vil'gel'm AE, Chumakov SP, Prasolov VS (2006) Mol Biol (Mosk) 40(3): 387-403
    › Primary publication · 16813159 (PubMed)
24. The gastrin gene promoter is regulated by p73 isoforms in tumor cells. Tomkova K, El-Rifai W, Vilgelm A, Kelly MC, Wang TC, Zaika AI (2006) Oncogene 25(44): 6032-6
    › Primary publication · 16636659 (PubMed)
25. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, Ellenson LH, Di Cristofano A (2006) Cancer Res 66(7): 3375-80
    › Primary publication · 16585156 (PubMed)

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword